Silence Therapeutics
Clinical-stage biotechnology company developing chemically modified short interfering RNA (siRNA) therapeutics with an emphasis on liver-directed delivery. The organisation designs and optimises oligonucleotide candidates, applies ligand-mediated hepatocyte targeting, advances programs from preclinical stages into Phase 1/2 clinical studies across hematology, cardiometabolic and rare-disease indications, and engages in external collaborations for discovery, development and commercialisation. The company maintains investor-facing services including public market listings and shareholder communications.
Industries
Nr. of Employees
medium (51-250)
Silence Therapeutics
London, England, United Kingdom
Products
Divesiran (SLN124)
siRNA candidate targeting TMPRSS6 developed to modulate iron regulation; evaluated in early-phase clinical studies for phlebotomy‑dependent polycythemia vera.
Zerlasiran (SLN360)
siRNA candidate targeting LPA to lower lipoprotein(a); evaluated in early-phase clinical studies for patients with elevated Lp(a).
SLN312 (ANGPTL3)
Oligonucleotide program targeting ANGPTL3 for dyslipidemia; program has been subject to an external licensing arrangement with a pharmaceutical partner during early development.
SLN548 (CFB), SLN365 (GPR146), SLN098 (INHBE)
Additional oligonucleotide discovery and development programs targeting complement biology, lipid metabolism and metabolic regulation in preclinical or early clinical stages.
SLN548
Investigational siRNA therapy targeting CFB for complement-mediated conditions.
mRNAi GOLD Platform
A proprietary delivery platform developed by Silence Therapeutics combining RNAi molecules with chemical address tags like GalNAc for targeted delivery to liver cells.
Divesiran (SLN124)
siRNA candidate targeting TMPRSS6 developed to modulate iron regulation; evaluated in early-phase clinical studies for phlebotomy‑dependent polycythemia vera.
Zerlasiran (SLN360)
siRNA candidate targeting LPA to lower lipoprotein(a); evaluated in early-phase clinical studies for patients with elevated Lp(a).
SLN312 (ANGPTL3)
Oligonucleotide program targeting ANGPTL3 for dyslipidemia; program has been subject to an external licensing arrangement with a pharmaceutical partner during early development.
SLN548 (CFB), SLN365 (GPR146), SLN098 (INHBE)
Additional oligonucleotide discovery and development programs targeting complement biology, lipid metabolism and metabolic regulation in preclinical or early clinical stages.
SLN548
Investigational siRNA therapy targeting CFB for complement-mediated conditions.
mRNAi GOLD Platform
A proprietary delivery platform developed by Silence Therapeutics combining RNAi molecules with chemical address tags like GalNAc for targeted delivery to liver cells.
Services
Collaborative discovery and partnering arrangements to co-develop siRNA and oligonucleotide therapeutic programs and delivery technologies.
Collaborative discovery and partnering arrangements to co-develop siRNA and oligonucleotide therapeutic programs and delivery technologies.
Expertise Areas
- siRNA and oligonucleotide therapeutic development
- Liver-targeted delivery and ligand conjugation
- Oligonucleotide chemistry and linker development
- Early-phase clinical trial management (Phase I/II)
Key Technologies
- siRNA design and RNA interference (RNAi)
- Ligand-conjugated oligonucleotide delivery (hepatocyte targeting)
- Oligonucleotide chemical modification for stability and activity
- Linker chemistry for bioconjugation
News & Updates
Webcast presenting topline Phase 2 SANRECO results for the divesiran clinical program.
Cancellation of admission of ordinary shares to trading on AIM took effect at 07:00 on 30 November 2021; shareholders were provided options to deposit shares for delivery of Nasdaq-listed American Depositary Shares (ADS), continue to hold unquoted ordinary shares, or sell prior to delisting.
Press release reporting positive topline Phase 2 results from the SANRECO trial of an siRNA candidate in polycythemia vera.
Conference poster and supporting publications describing clinical and preclinical findings for a GalNAc-conjugated siRNA program (SANRECO Phase 1 results and related preclinical studies).
Reported positive topline results from a Phase 2 clinical trial evaluating an siRNA candidate in polycythemia vera.
Webcast presenting topline Phase 2 SANRECO results for the divesiran clinical program.
Cancellation of admission of ordinary shares to trading on AIM took effect at 07:00 on 30 November 2021; shareholders were provided options to deposit shares for delivery of Nasdaq-listed American Depositary Shares (ADS), continue to hold unquoted ordinary shares, or sell prior to delisting.
Press release reporting positive topline Phase 2 results from the SANRECO trial of an siRNA candidate in polycythemia vera.
Conference poster and supporting publications describing clinical and preclinical findings for a GalNAc-conjugated siRNA program (SANRECO Phase 1 results and related preclinical studies).
Reported positive topline results from a Phase 2 clinical trial evaluating an siRNA candidate in polycythemia vera.